Muhammad Umair Mushtaq: Impact of MRD on Outcomes After Allo-HCT for AML
Muhammad Umair Mushtaq, Associate Professor of Hematologic Malignancies and Cellular Therapeutics at the University of Kansas Medical Center, shared a post on X about a paper he co-authored with colleagues, published in Clinical Lymphoma Myeloma and Leukemia:
“Impact of MRD on outcomes after allo-HCT for AML.”
Title: Impact of Measurable Residual Disease Status on Outcomes after HLA-Matched Donor Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia
Authors: Moazzam Shahzad, Muhammad Kashif Amin, Sohaib Irfan, Abhinav Vyas, Rania Ahsan, Sibgha Gull Chaudhary, Iqra Anwar, Matthew McGuirk, Raheel Iftikhar, Haitham Abdelhakim, Anurag K. Singh, Mehdi Hamadani, Joseph P. Mcguirk, Muhammad Umair Mushtaq
You can read the Full Article in Clinical Lymphoma Myeloma and Leukemia.
More posts featuring Muhammad Umair Mushtaq on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023